|
| 鲑鱼降钙素注射液与唑来膦酸钠注射液治疗绝经后骨质疏松症的临床疗效对比 |
| Clinical comparison of salmon calcitonin and zoledronic acid injection in the treatment of postmenopausal osteoporosis |
| |
| DOI：10.3969/j.issn.1006-7108.2018.08.013 |
| 中文关键词: 鲑鱼降钙素注射液 唑来膦酸钠注射液 绝经后骨质疏松症 骨密度 视觉模拟标度尺 |
| 英文关键词:Zoledronic acid Salmon calcitonin Postmenopausal osteoporosis BMD visual analogue scale |
| 基金项目: |
|
| 摘要点击次数: 951 |
| 全文下载次数: 711 |
| 中文摘要: |
| 目的 对比鲑鱼降钙素注射液与唑来膦酸钠注射液在治疗绝经后骨质疏松症的临床疗效研究。方法 本研究收集了2010 年 2 月-2016 年 2 月在南昌大学第三附属医院治疗的绝经后骨质疏松症患者82例，分为鲑鱼降钙素注射液治疗组（40 例，治疗时间3个月/年，连续3年），唑来膦酸钠注射液组（42例，治疗时间1次/年，5 mg/次，连续3年）。同时口服碳酸钙D3（600 mg/d）、骨化三醇（0.25μg /d）。采集患者基线及治疗3年后骨密度（bone mineral density，BMD）、肾功能、血钙（blood calcium，BC）、血磷（blood phosphorus BP）、骨碱性膦酸酶（bone alkaline phosphatase，BALP）；进行组间及治疗前后对照；以视觉模拟标度尺（visual analogue scale ,VAS）评分评估骨痛情况，判定临床疗效；对比两组患者不良反应的发生人次及发生率。结果 ①对两组患者肾功能、血钙、血磷、骨碱性膦酸酶水平进行组间及治疗前后比较，差异均无统计学意义，P＞0.05；②两组患者治疗后骨痛评价：两组患者VAS 评分均较治疗前降低，但鲑鱼降钙素组VAS 评分较唑来膦酸钠组显著降低，差异有统计学意义，P＜0.05；③两组患者治疗后面积骨密度值较治疗前均显著升高，P＜0.05。唑来膦酸钠组患者腰椎、股骨颈骨密度升高幅度高于鲑鱼降钙素组，两组比较差异有统计学意义，P＜0.05；④在本研究中唑来膦酸钠组不良反应发生率低。结论 唑来膦酸钠与鲑鱼降钙素治疗3年均有效提高了绝经后骨质疏松症患者的骨密度，其中唑来膦酸钠组优于鲑鱼降钙素组。两种治疗均有效减轻患者骨痛症状，鲑鱼降钙素组临床疗效优于唑来膦酸钠组。 |
| 英文摘要: |
| Objective To investigate the therapeutic effect of salmon calcitonin and zoledronic acid injection in the treatment of postmenopausal osteoporosis, with the aim of providing clinical evidence for the treatment of these patients. Methods 82 patients with osteoporosis were observed in our hospital from February 2010 to February 2016, among them 40 were in the salmon calcitonin group, with the course of treatment 3 months per year, continued for 3 years; 42 were in the zoledronic acid group, with the frequency of treatment once per year, continued for 3 years. At the same time, patients received calcium (600 mg/day) and vitamin?D (0.25ug/day). Before and after treatment, bone mineral density (BMD) and biochemical indexes (liver and kidney function, blood calcium, blood phosphorus and bone alkaline phosphatase) were assessed and compared within and between the two groups. Improvement in pain symptoms was assessed using visual analogue scale (VAS) and incidence of adverse drug reaction were observed. Results The mean age was 65.23±7.36 years in the salmon calcitonin group and 66.79±8.65 in the zoledronic acid group. ① There were no significant differences between the two groups or within each group before and after treatment in kidney function, blood calcium, blood phosphorus and BALP (all P >0.05). ② VAS score of the two groups after treatment was lower than before treatment, and the score of the salmon calcitonin group decreased significantly (P < 0.05). ③ After treatment, BMD of the two groups was significantly higher than before treatment. BMD of lumbar vertebra and femoral neck in zoledronic acid group was higher than that in salmon calcitonin group, and the difference between the two groups was statistically significant (P < 0.05). ④ The incidence of adverse reactions in zoledronic acid group was lower. Conclusions Zoledronic acid and salmon calcitonin injection both could improve BMD effectively, and zoledronic acid group was more effective in increasing BMD in postmenopausal osteoporosis patients. The above two injections could alleviate bone pain symptoms, and salmon calcitonin had better effect than zoledronic acid injection. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|